alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, May 19, 2022. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, May 19, 2022 The Court of Appeals hereby passes the following order A22D0365. CHERIE LONG v. DUANE TRUEX.
Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby GRANTED. The Appellant may file a Notice of Appeal within 10 days of the date of this order. The Clerk of Superior Court is directed to include a copy of this order in the record transmitted to the Court of Appeals.
LC NUMBERS: 15CV3807
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10327]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4573]


-----------------------------------------------------------------------

DEPARTMENT OF LABOR

Employment and Training Administration

[TA-W-71,233]


Advance Accessory Systems, Shelbyville, MI; Notice of Termination 
of Certification

    Pursuant to Section 221 of the Trade Act of 1974, as amended, a 
certification was issued on December 10, 2009 in response to a worker 
petition filed on behalf of workers at Advance Accessory Systems, 
Shelbyville, Michigan.
    The petitioning group of workers is covered by an active 
certification (TA-W-70,522A), which expires on July 23, 2011. 
Therefore, to avoid duplication in certification issued on December 10, 
2009, TA-W-71,233 has been terminated.

    Signed at Washington, DC, this 24th day of February 2010.
Elliott S. Kushner,
Certifying Officer, Division of Trade Adjustment Assistance.
[FR Doc. 2010-4573 Filed 3-4-10; 8:45 am]
BILLING CODE 4510-FN-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Reserve System

                    The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage                     *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.                

                    Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at                     *www.ffiec.gov/​nic/​*.                

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 25, 2010.

**A. Federal Reserve Bank of Philadelphia**                     (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:                

*1. Bryn Mawr Bank Corporation*, Bryn Mawr, Pennsylvania; to acquire First Keystone Financial, Inc. Media, Pennsylvania, and thereby indirectly acquire First Keystone Bank, Media, Pennsylvania, and thereby engage in operating a savings and loan assocation, pursuant to 225.28(b)(4)(ii) of Regulation Y.                

Board of Governors of the Federal Reserve System, February 23, 2010.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 2010-3991 Filed 2-25-10; 8:45 am]

BILLING CODE 6210-01-S
<PAGE>   1

                         CONSENT OF INDEPENDENT AUDITORS
--------------------------------------------------------------------------------



The Board of Directors
INTERLINQ Software Corporation:


We consent to the incorporation by reference in the registration statements
(Nos. 33-63388, 333-04558 and 333-21099) on Form S-8 of INTERLINQ Software
Corporation of our report dated July 30, 1998, except for notes 1(q), 3 and 5
which are as of March 8, 1999, relating to the balance sheets of INTERLINQ
Software Corporation as of June 30, 1998 and 1997, and the related statements of
operations, shareholders' equity, and cash flows for each of the years in the
three-year period ended June 30, 1998, and the related schedule, which report
appears in the June 30, 1998, annual report on Form 10-K/A of INTERLINQ Software
Corporation.



/s/ KPMG LLP


Seattle, Washington
March 8, 1999







58
#### § 350.60 Guidelines for effectiveness testing of antiperspirant drug products.

An antiperspirant in finished dosage form may vary in degree of effectiveness because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food and Drug Administration is providing guidelines that manufacturers may use in testing for effectiveness. These guidelines are on file in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. These guidelines are available on the FDA's web site at *http://www.fda.gov/cder/otc/index.htm* or on request for a nominal charge by submitting a Freedom of Information (FOI) request in writing to FDA's Division of Freedom of Information (address is located on the agency's web site at *http://www.fda.gov.*

[68 FR 34291, June 9, 2003, as amended at 76 FR 31470, June 1, 2011; 79 FR 68115, Nov. 14, 2014; 88 FR 45066, July 14, 2023]
Exhibit 32



                     GE GLOBAL INSURANCE HOLDING CORPORATION
                          AND CONSOLIDATED SUBSIDIARIES



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350


     In  connection  with the  Annual  Report  of GE  Global  Insurance  Holding
     Corporation  (the  "Company") on Form 10-K for the year ended  December 31,
     2003,  as filed with the  Securities  and Exchange  Commission  on the date
     hereof (the  "Report"),  we, Ronald R. Pressman and Marc A. Meiches,  Chief
     Executive  Officer  and  Chief  Financial  Officer,  respectively,  of  the
     Registerant, certify, pursuant to 18 U.S.C. ss. 1350, that to my knowledge:

          (1)  The Report fully complies with the  requirements of section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

          (2)  The information  contained in the Report fairly presents,  in all
               material  respects,   the  financial   condition  and  result  of
               operations of the Company.







     /s/ Ronald R. Pressman
     Ronald R. Pressman
     Chief Executive Officer
     March 1, 2004





     /s/ Marc A. Meiches
     Marc A. Meiches
     Chief Financial Officer
     March 1, 2004
118TH CONGRESS 

1ST SESSION H. R. 753 

AN ACT 

To direct the Secretary of Veterans Affairs to use on-site 

regulated medical waste treatment systems at certain 

Department of Veterans Affairs facilities, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 753 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Department of Vet3 erans Affairs Creation of On-Site Treatment Systems Af4 fording Veterans Improvements and Numerous General 

5 Safety Enhancements Act’’ or the ‘‘VA COST SAVINGS 

6 Enhancements Act’’. 

7 SEC. 2. USE OF ON-SITE REGULATED MEDICAL WASTE 

8 TREATMENT SYSTEMS AT DEPARTMENT OF 

9 VETERANS AFFAIRS FACILITIES. 

10 (a) IDENTIFICATION OF FACILITIES.—The Secretary 

11 of Veterans Affairs shall identify Department of Veterans 

12 Affairs facilities that would benefit from cost savings asso13 ciated with the use of an on-site regulated medical waste 

14 treatment system over a five-year period. 

15 (b) REGULATED MEDICAL WASTE COST ANALYSIS

16 MODEL.—For purposes of carrying out subsection (a), the 

17 Secretary shall develop a uniform regulated medical waste 

18 cost analysis model to be used to determine the cost sav19 ings associated with the use of an on-site regulated med20 ical waste treatment system at Department facilities. Such 

21 model shall be designed to calculate savings based on— 

22 (1) the cost of treating regulated medical waste 

23 at an off-site location under a contract with a non24 Department entity; compared to 

25 (2) the cost of treating regulated medical waste 

26 on-site, based on the equipment specification of 
3 

•HR 753 EH

1 treatment system manufacturers, with capital costs 

2 amortized over a ten-year period. 

3 (c) INSTALLATION.—At each Department facility 

4 identified under subsection (a), the Secretary shall secure, 

5 install, and operate an on-site regulated medical waste 

6 treatment system. 

7 (d) REGULATED MEDICAL WASTE DEFINED.—In 

8 this section, the term ‘‘regulated medical waste’’ has the 

9 meaning given such term under section 173.134(a)(5) of 

10 title 49, Code of Federal Regulations, concerning regu11 lated medical waste and infectious substances, or any suc12 cessor regulation, except that, in the case of an applicable 

13 State law that is more expansive, the definition in the 

14 State law shall apply. 

15 SEC. 3. NO ADDITIONAL FUNDS AUTHORIZED. 

16 No additional funds are authorized to be appro17 priated to carry out the requirements of this Act. 

Passed the House of Representatives March 8, 

2023. 

Attest: 

Clerk. 
118TH CONGRESS 

1ST SESSION H. R. 753 

AN ACT 

To direct the Secretary of Veterans Affairs to use 

facilities, and for other purposes. tems at certain Department of Veterans Affairs on-site regulated medical waste treatment sys-
§ 82.5 General specifications for straight colors. No batch of a straight color listed in subpart B, C, or D shall be certified under this part unless: ( a ) It is free from all impurities (other than those named in paragraph (b) of this section or in the specifications set forth in such paragraph for such color) to the extent that such impurities can be avoided by good manufacturing practice.
( b ) It conforms to the following specifications: ( 1 ) In the case of a straight color listed in subpart B: ( i ) Lead (as Pb), not more than 0.001 percent.
( ii ) Arsenic (as As2O3), not more than 0.00014 percent.
( iii ) Heavy metals (except Pb and As) (by precipitation as sulfides), not more than trace.
( 2 ) In the case of a straight color listed in subpart C or D: ( i ) Lead (as Pb), not more than 0.002 percent.
( ii ) Arsenic (as As2O3), not more than 0.0002 percent.
( iii ) Heavy metals (except Pb and As) (by precipitation as sulfides), not more than 0.003 percent.
( 3 ) In the case of a straight color which contains a barium salt listed in subpart C or D—soluble barium (in dilute HCl) (as BaCl2), not more than 0.05 percent.
# C_2014184EN.01004001.xml

| 16.6.2014 | EN | Official Journal of the European Union | C 184/40 |
| --- | --- | --- | --- |

16.6.2014

EN

Official Journal of the European Union

C 184/40

---

Action brought on 7 February 2014 — ZZ v CdT

(Case F-12/14)

2014/C 184/65

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: N. Cambonie, D. Ciolino and E. Macchi, lawyers)

Applicant:

Defendant: Translation Centre for the Bodies of the European Union (CdT)

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision of the Translation Centre for the Bodies of the European Union rejecting the request made by the applicant on the basis of Article 90(1) of the Staff Regulations to adopt a decision apologising to him and granting him compensation for the damage suffered.

Form of order sought

Form of order sought

The applicant claims that the Tribunal should:

| — | annul the CdT’s implied rejection, or otherwise annul the rejection in the letter produced by the lawyer representing the CdT containing the decision of 10 April 2013 and, so far as necessary, the confirmatory decision of the CdT of 8 November 2013 rejecting the applicant’s request for it to take a decision; |
| --- | --- |

—

annul the CdT’s implied rejection, or otherwise annul the rejection in the letter produced by the lawyer representing the CdT containing the decision of 10 April 2013 and, so far as necessary, the confirmatory decision of the CdT of 8 November 2013 rejecting the applicant’s request for it to take a decision;

| — | declare the CdT liable for the damage suffered by the applicant, and consequently grant the applicant damages amounting to EUR 306 733,60 in respect of material loss and EUR 130 000 in respect of non-material loss, or any other, possibly greater, sum to be determined by the Tribunal, or else by expert evidence; |
| --- | --- |

—

declare the CdT liable for the damage suffered by the applicant, and consequently grant the applicant damages amounting to EUR 306 733,60 in respect of material loss and EUR 130 000 in respect of non-material loss, or any other, possibly greater, sum to be determined by the Tribunal, or else by expert evidence;

| — | order the CdT to pay the costs. |
| --- | --- |

—

order the CdT to pay the costs.

---
§ 806.1 Scope. ( a ) This part implements the provisions of section 519(g) of the Federal Food, Drug, and Cosmetic Act (the act) requiring device manufacturers and importers to report promptly to the Food and Drug Administration (FDA) certain actions concerning device corrections and removals, and to maintain records of all corrections and removals regardless of whether such corrections and removals are required to be reported to FDA.
( b ) The following actions are exempt from the reporting requirements of this part: ( 1 ) Actions taken by device manufacturers or importers to improve the performance or quality of a device but that do not reduce a risk to health posed by the device or remedy a violation of the act caused by the device.
( 2 ) Market withdrawal as defined in § 806.2(i)
( 3 ) Routine servicing as defined in § 806.2(l).
( 4 ) Stock recovery as defined in § 806.2(m).
[62 FR 27191, May 19, 1997, as amended at 63 FR 42232, Aug. 7, 1998; 84 FR 12083, Apr. 1, 2019]
§ 74.2333 D&C Red No. 33. ( a ) *Identity and specifications.* The color additive D&C Red No. 33 shall conform in identity and specifications to the requirements of § 74.1333(a) (1) and (b).
( b ) *Uses and restrictions.* The color additive D&C Red No. 33 may be safely used for coloring cosmetic lip products in amounts not to exceed 3 percent total color by weight of the finished cosmetic products. D&C Red No. 33 may be safely used for coloring mouthwashes (including breath fresheners), dentifrices, and externally applied cosmetics in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 33 shall be certified in accordance with regulations in part 80 of this chapter.
[53 FR 33120, Aug. 30, 1988]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Wage Chronology: United States Steel Corporation and United Steelworkers of America (AFL-CIO), March 1937-April 1974

              																	United States. Bureau of Labor Statistics. 						*Wage Chronology: United States Steel Corporation and United Steelworkers of America (AFL-CIO), March 1937-April 1974 : Bulletin of the United States Bureau of Labor Statistics, No. 1814*,												Washington, D.C: 								U.S. Dept. of Labor Bureau of Labor Statistics, 										1974,									https://fraser.stlouisfed.org/title/4910,			accessed on September 26, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
<PAGE>
                                                                 Exhibit 10.13.3

                                 THIRD AMENDMENT

                                       to

                             2000 STOCK OPTION PLAN

                                       of

                           DAYTON SUPERIOR CORPORATION

     Section 2.1(a) of the 2000 Stock Option Plan of Dayton Superior Corporation
(the "Plan") hereby is amended in its entirety, effective as of October 23,
2002, to read as follows:

     "2.1 Shares Subject to Plan.

          (a) The shares of stock subject to Options shall be shares of the
     Company's Common Stock. The aggregate number of such shares which may be
     issued upon exercise of such Options shall not exceed 719,254 as adjusted
     pursuant to Section 8.3. The shares of Common Stock issuable upon exercise
     of such Options may be either previously authorized but unissued shares or
     treasury shares."

     The foregoing amendment to the Plan was approved by the directors of Dayton
Superior Corporation (the "Company") acting at a meeting duly called and held on
October 23, 2002 and shall be submitted to the shareholders of the Company for
approval within 12 months after the date of such meeting.

     Except as expressly set forth above, the Plan is not hereby modified or
amended and shall remain in full force and effect accordance with its terms.

     IN WITNESS WHEREOF, the undersigned has executed this Third Amendment as of
the date first set forth above.

                                          DAYTON SUPERIOR CORPORATION


                                          By: /s/ John A. Ciccarelli
                                             Name: John A. Ciccarelli
                                             Title: Chairman of the Board of
                                                    Directors
# C_2014235EN.01003501.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/35 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/35

---

Action brought on 22 May 2014 — ZZ v Commission

(Case F-48/14)

2014/C 235/47

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: R. Duta, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment, firstly, of the decision of 14 February 2014 by which the selection board in selection procedure EU Careers EPSO/AD/177/10-AUDIT2013-Administrators-AD 5 confirmed, after re-examination, the initial decision of the selection board of 3 October 2013 not to admit the applicant to the assessment centre stage of the competition and, secondly, insofar as necessary, of the initial decision of the selection board of 3 October 2013.

EPSO/AD/177/10-AUDIT2013-Administrators-AD 5

Form of order sought

Form of order sought

| — | Annul the decisions of the competition selection board of 14 February 2014 and 3 October 2013 pursuant to which her application to competition EPSO/AD/177/10-AUDIT2013-Administrators-AD 5 was rejected; |
| --- | --- |

—

Annul the decisions of the competition selection board of 14 February 2014 and 3 October 2013 pursuant to which her application to competition EPSO/AD/177/10-AUDIT2013-Administrators-AD 5 was rejected;

EPSO/AD/177/10-AUDIT2013-Administrators-AD 5

| — | Make any other appropriate orders in that regard; |
| --- | --- |

—

Make any other appropriate orders in that regard;

| — | Order the Commission to pay an amount of EUR 5  000, or any other amount, even greater, to be determined by the Civil Service Tribunal ex aequo et bono, in compensation for the vexatious nature of the treatment of her application; |
| --- | --- |

—

Order the Commission to pay an amount of EUR 5  000, or any other amount, even greater, to be determined by the Civil Service Tribunal ex aequo et bono, in compensation for the vexatious nature of the treatment of her application;

ex aequo et bono

| — | Order the Commission to pay all the costs of the case. |
| --- | --- |

—

Order the Commission to pay all the costs of the case.

---
**Exhibit32.1**

 

**CERTIFICATIONPURSUANT TO**

 

**18U.S.C. SECTION 1350,**

 

**ASADOPTED PURSUANT TO**

 

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Quarterly Report onForm 10-Q of Ebix, Inc. (the “Company”) for the quarterly period ended September30, 2004, as filed with the Securities and Exchange Commission on the datehereof (the “Report”), I, Robin Raina, Chief Executive Officer of the Company,certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of theSarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of section 13(a)or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 

 
| By:                     | /s/ Robin Raina |   |
|-------------------------|-----------------|--------|
|                    |            |
| Name:                   | Robin Raina     |   |
|                    |            |
| Chief Executive Officer |            |
|                    |            |
| November 15, 2004  |            |
|                         |                 |        |  |

 

1

----
#### § 601.93 Postmarketing safety reporting.

Biological products approved under this subpart are subject to the postmarketing recordkeeping and safety reporting applicable to all approved biological products.